

Drug Monograph

Drug/Drug **Dextenza® (dexamethasone) ophthalmic insert) /**
 Class: **Intravitreal Steroids**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Dextenza is available as an intracanalicular insert containing a 0.4mg dose of dexamethasone.

Manufacturer: Distributed by: Ocular Therapeutic, Inc, Bedford MA 01730

Indications: Dextenza is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

Costs: \$538.83 per insert of Dextenza. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications Under Solicitation

Prepared by: Jaci Schowengerdt, PharmD
 Date: August 27, 2019